| Therapeutic | Ofatumumab |
| Target | MS4A1/CD20 |
| Heavy Chain | EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK |
| 100% seqID Fv Structure | 3giz [Fvs: HL], 6y92 [Fvs: CD, HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3giz [Fvs: HL] |
| 100% seqID Structure | 6y92 [Fvs: CD, HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | Medarex HuMAb Mouse |
| INN Year Proposed | 2005 |
| INN Year Recommended | 2006 |
| Companies Involved | Genmab, GlaxoSmithKline, Mundipharma International, National Cancer Centre (Singapore), Novartis, Roswell Park Cancer Institute, University Health Network |
| Conditions Approved | Chronic lymphocytic leukaemia |
| Conditions Active | B-cell lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Multiple sclerosis, Marginal zone B-cell lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Discontinued | Neuromyelitis optica, Pemphigus vulgaris, Rheumatoid arthritis, Waldenstrom's macroglobulinaemia |
| Notes | Biosimilars available |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
